Wedoany.com Report-Dec.11, Pfizer plans to reduce its workforce in Switzerland by more than 200 positions before the end of 2025. The adjustment will bring the total number of employees in the country to approximately 70, down from around 300 currently.

The move forms part of Pfizer's ongoing multi-year cost-saving initiative, which targets total savings of approximately $7.7 billion by the end of 2027. The program follows lower revenue from COVID-related products after the peak of the pandemic and aims to improve operational efficiency across the company.

The Swiss unit has undergone a structural review that resulted in a reduced operational scope. In September, Pfizer appointed Rea Lal as the new country head for Switzerland, succeeding Sabine Bruckner, who moved to a different role within the international organization. Lal now oversees the smaller local team.

Pfizer has not issued an official statement in response to requests for comment on the reported staff reduction.

The adjustment affects only the company's presence in Switzerland and does not involve changes to manufacturing, imports, exports, or product consumption in any market. It reflects broader efforts by several large pharmaceutical companies to streamline operations and redirect resources toward research, development, and growth areas.

For context, Novartis announced last month that it intends to reduce up to 550 full-time positions at one of its Swiss facilities by the end of 2027 as part of its own efficiency measures. Both announcements illustrate ongoing organizational adaptations within the pharmaceutical sector in Switzerland, where many global companies maintain significant research, development, and commercial activities.

Pfizer continues to operate in Switzerland with a focus on essential functions while implementing the planned workforce transition in line with its global cost-management objectives. The changes are scheduled to be completed by the end of the current year.